(Q35771532)

10 August 2017

1 reference

title

Spotlight on the pharmacoeconomics of escitalopram in depression (English)

1 reference

10 August 2017

1 reference

2

Greg L Plosker

1 reference

10 August 2017

Katherine F Croom

1

1 reference

10 August 2017

language of work or name

1 reference

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

469-473

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

10 August 2017

cites work

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

The costs of depression.

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

12 December 2020

Suicide risk in patients with major depressive disorder.

1 reference

12 December 2020

Cross-national epidemiology of major depression and bipolar disorder

1 reference

12 December 2020

Major depression and all-cause mortality among white adults in the United States

1 reference

12 December 2020

Depressive disorders in Europe: prevalence figures from the ODIN study

1 reference

12 December 2020

Comparison of escitalopram and citalopram efficacy: A meta-analysis

1 reference

12 December 2020

Depression in the community: the first pan-European study DEPRES (Depression Research in European Society)

1 reference

12 December 2020

Depression: cost-of-illness studies in the international literature, a review

1 reference

12 December 2020

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

12 December 2020

Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

1 reference

12 December 2020

Comorbidity of mood disorders: a longitudinal prospective study

1 reference

12 December 2020

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

12 December 2020

Optimizing outcomes in depression: focus on antidepressant compliance

1 reference

12 December 2020

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Minor and major depression and the risk of death in older persons

1 reference

12 December 2020

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway

1 reference

12 December 2020

Long-term nature of depression

1 reference

12 December 2020

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

The prevalence of depressive disorders in the United Kingdom.

1 reference

12 December 2020

The economic burden of depression in 1990.

1 reference

12 December 2020

10.2165/00023210-200418070-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1023619875

0 references

1 reference